Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075165 Target Snapshot

Phosphatidylinositol 3-kinase catalytic subunit type 3 · SINGLE PROTEIN · Homo sapiens

1,477Compounds
226Assays
2Approved Drugs
1,823.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q8NEB9. Use UniProt Q8NEB9 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q8NEB9 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Phosphatidylinositol 3-kinase catalytic subunit type 3 as ChEMBL target CHEMBL1075165, mapped to UniProt Q8NEB9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Phosphatidylinositol 3-kinase catalytic subunit type 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1075165
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q8NEB9
Phosphatidylinositol 3-kinase catalytic subunit type 3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Phosphatidylinositol 3-kinase catalytic subunit type 3 is the right protein anchor across sources, using UniProt Q8NEB9 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPhosphatidylinositol 3-kinase catalytic subunit type 3
UniProt AccessionQ8NEB9
Component TypeProtein
Sequence Length887 aa

Phosphatidylinositol 3-kinase catalytic subunit type 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Phosphatidylinositol 3-kinase catalytic subunit type 3, mapped to UniProt Q8NEB9. Sequence length is 887 aa.

Mapped IDQ8NEB9
Review namePhosphatidylinositol 3-kinase catalytic subunit type 3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

2
Approved
5
Phase III
15
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC501,732.0
KI37.0
EC5014.0
KD40.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL273832 9.3 IC50 0.5 Preclinical
CHEMBL5286775 9.28 Kd 0.53 Preclinical
CHEMBL3622372 9.0 IC50 1.0 Preclinical
CHEMBL5404351 9.0 Kd 1.0 Preclinical
CHEMBL5982739 9.0 IC50 1.0 Preclinical
CHEMBL3622372 8.96 EC50 1.11 Preclinical
CHEMBL4561242 8.8 IC50 1.585 Preclinical
CHEMBL2140173 8.77 Kd 1.7 Preclinical
CHEMBL5192406 8.77 IC50 1.7 Preclinical
CHEMBL4517404 8.7 IC50 2.0 Preclinical
Distribution

pChEMBL Value Distribution

48
5.0
46
5.5
41
6.0
71
6.5
178
7.0
574
7.5
50
8.0
20
8.5
6
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PANOBINOSTAT
CHEMBL483254
Approved 2015
IDELALISIB
CHEMBL2216870
Approved 2014
Assay Landscape

Assay Landscape

226
Total Assays
695
Tested Compounds
3
Assay Types
Binding — 221 assays, 695 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 122 555 7.4
cell-based format 43 34 7.1
assay format 31 106 6.1
subcellular format 25 0
ADME — 4 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 3 10 7.4
tissue-based format 1 1 7.0
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine